23rd Jan 2015 07:52
LONDON (Alliance News) - Molecular diagnostics company EKF Diagnostic Holdings PLC on Friday said it has agreed a deal with medical technology company ANGLE PLC to investigate combining EKF's PointMan DNA enrichment technology with ANGLE's Parsotix circulating tumour cell harvesting platform.
The deal will initially focused on work on colorectal cancer and will then expand to other cancer types. Circulating tumour cells will be harvested via Parsotix and then analysed using PointMan's technology to identify genetic variation in the cancer.
The pair, which are both listed on AIM, did not provide any financial details on the contract.
"Our PointMan DNA enrichment technology has demonstrable performance in the detection of ultra-low level mutations. The high purity of the CTCs harvested by ANGLE's Parsortix system and the absence of immunomagnetic beads gives us confidence that it will be effective with the Parsortix harvested CTCs providing rapid molecular information to the oncologist," said EKF Chief Executive Officer Julian Baines.
"We are delighted to announce this collaboration with EKF. The combination of ANGLE's Parsortix system with EKF's PointMan system has the potential to provide a complete solution for the oncologist. We look forward to an early proof-of-principle," said ANGLE Chief Executive Andrew Newland.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
AngleEkf Diagnostics